WO2009042444A3 - Procédés et composés pour le traitement de maladies liées au rétinol - Google Patents

Procédés et composés pour le traitement de maladies liées au rétinol Download PDF

Info

Publication number
WO2009042444A3
WO2009042444A3 PCT/US2008/076499 US2008076499W WO2009042444A3 WO 2009042444 A3 WO2009042444 A3 WO 2009042444A3 US 2008076499 W US2008076499 W US 2008076499W WO 2009042444 A3 WO2009042444 A3 WO 2009042444A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
methods
related diseases
treat
retinol
Prior art date
Application number
PCT/US2008/076499
Other languages
English (en)
Other versions
WO2009042444A2 (fr
Inventor
Nathan L Mata
Kim B Phan
Tam V Bui
Mustapha Haddach
Original Assignee
Sirion Therapeutics Inc
Nathan L Mata
Kim B Phan
Tam V Bui
Mustapha Haddach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirion Therapeutics Inc, Nathan L Mata, Kim B Phan, Tam V Bui, Mustapha Haddach filed Critical Sirion Therapeutics Inc
Priority to EP08834564A priority Critical patent/EP2205234A4/fr
Priority to CA2699773A priority patent/CA2699773A1/fr
Priority to AU2008305303A priority patent/AU2008305303A1/en
Priority to JP2010527024A priority patent/JP2010540541A/ja
Priority to CN200880107835A priority patent/CN101873852A/zh
Publication of WO2009042444A2 publication Critical patent/WO2009042444A2/fr
Publication of WO2009042444A3 publication Critical patent/WO2009042444A3/fr
Priority to IL204728A priority patent/IL204728A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Les composés qui réduisent les taux de rétinol dans le sérum sont utilisés pour traiter des états ophtalmiques associés à la surproduction de produits résiduaires qui s'accumulent pendant le cours du cycle visuel. Nous décrivons des procédés, des composés et des compositions pour traiter, par exemple, les dégénérescences maculaires et les dystrophies maculaires ou pour soulager des symptômes associés à de tels états ophtalmiques.
PCT/US2008/076499 2007-09-27 2008-09-16 Procédés et composés pour le traitement de maladies liées au rétinol WO2009042444A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP08834564A EP2205234A4 (fr) 2007-09-27 2008-09-16 Procédés et composés pour le traitement de maladies liées au rétinol
CA2699773A CA2699773A1 (fr) 2007-09-27 2008-09-16 Procedes et composes pour le traitement de maladies liees au retinol
AU2008305303A AU2008305303A1 (en) 2007-09-27 2008-09-16 Methods and compounds for treating retinol-related diseases
JP2010527024A JP2010540541A (ja) 2007-09-27 2008-09-16 レチノール関連疾患を治療するための方法及び化合物
CN200880107835A CN101873852A (zh) 2007-09-27 2008-09-16 治疗视黄醇相关性疾病的方法和化合物
IL204728A IL204728A0 (en) 2007-09-27 2010-03-25 Methods and compounds for treating retinol-related diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97576507P 2007-09-27 2007-09-27
US60/975,765 2007-09-27
US98132207P 2007-10-19 2007-10-19
US60/981,322 2007-10-19

Publications (2)

Publication Number Publication Date
WO2009042444A2 WO2009042444A2 (fr) 2009-04-02
WO2009042444A3 true WO2009042444A3 (fr) 2009-05-14

Family

ID=40512081

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/076499 WO2009042444A2 (fr) 2007-09-27 2008-09-16 Procédés et composés pour le traitement de maladies liées au rétinol

Country Status (8)

Country Link
EP (1) EP2205234A4 (fr)
JP (1) JP2010540541A (fr)
KR (1) KR20100097098A (fr)
CN (1) CN101873852A (fr)
AU (1) AU2008305303A1 (fr)
CA (1) CA2699773A1 (fr)
IL (1) IL204728A0 (fr)
WO (1) WO2009042444A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586571B2 (en) 2007-10-18 2013-11-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2010119992A1 (fr) 2009-04-16 2010-10-21 Takeda Pharmaceutical Company Limited Dérivés de n-acyl-n'-phénylpipérazine utiles (notamment) pour la prévention ou le traitement du diabète
US8980924B2 (en) 2010-11-24 2015-03-17 The Trustees Of Columbia University In The City Of New York Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease
KR20140001224A (ko) * 2010-12-02 2014-01-06 다이이찌 산쿄 가부시키가이샤 수식 1 개 사슬 폴리뉴클레오티드
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
EP2968304B1 (fr) 2013-03-14 2018-10-10 The Trustees of Columbia University in the City of New York 4-phénylpipéridines, leur préparation et leur utilisation
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
BR112016025356B1 (pt) 2014-04-30 2023-04-18 The Trustees Of Columbia University In The City Of New York Compostos de 4-fenilpiperidinas substituídas, composições e seus usos
US9944596B2 (en) * 2014-10-24 2018-04-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN115197160A (zh) 2014-10-24 2022-10-18 武田药品工业株式会社 杂环化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS577480A (en) * 1980-06-16 1982-01-14 Sankyo Co Ltd 4-alkoxy-6-phenoxymethyl-2-pyrone derivative
WO2005116010A1 (fr) * 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Agoniste du recepteur ep4, compositions et methodes associees ep4 receptor agonist, compositions and methods thereof
US20060140953A1 (en) * 2004-01-08 2006-06-29 Evan Newell Systems and methods for treating human inflammatory and proliferative diseases and wounds, with UCP and/or FAS antibody or other inhibitor, optionally with a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2526534A (en) * 1948-07-03 1950-10-17 Dow Chemical Co Di-(aryloxy)-methanes
US4255152A (en) * 1978-09-05 1981-03-10 Ciba-Geigy Corporation Process for the dyeing of hydrophobic fibres
WO2005092062A2 (fr) * 2004-03-19 2005-10-06 Myriad Genetics, Inc. Composes destines aux troubles neurodegeneratifs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS577480A (en) * 1980-06-16 1982-01-14 Sankyo Co Ltd 4-alkoxy-6-phenoxymethyl-2-pyrone derivative
US20060140953A1 (en) * 2004-01-08 2006-06-29 Evan Newell Systems and methods for treating human inflammatory and proliferative diseases and wounds, with UCP and/or FAS antibody or other inhibitor, optionally with a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
WO2005116010A1 (fr) * 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Agoniste du recepteur ep4, compositions et methodes associees ep4 receptor agonist, compositions and methods thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SWAPNIL S. MOHILE ET AL.: "Ionic liquids: efficient additives for Candida rugosa lipase- catalysed enantioselective hydrolysis of butyl 2-(4-chlorophenoxy)propionate", JOURNAL OF MOLECULAR CATALYSIS B: ENZYMATIC, vol. 30, no. 5-6, 1 September 2004 (2004-09-01), pages 185 - 188, XP008132954 *

Also Published As

Publication number Publication date
EP2205234A2 (fr) 2010-07-14
CN101873852A (zh) 2010-10-27
JP2010540541A (ja) 2010-12-24
AU2008305303A1 (en) 2009-04-02
WO2009042444A2 (fr) 2009-04-02
KR20100097098A (ko) 2010-09-02
CA2699773A1 (fr) 2009-04-02
EP2205234A4 (fr) 2010-12-22
IL204728A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
WO2009042444A3 (fr) Procédés et composés pour le traitement de maladies liées au rétinol
WO2007008821A3 (fr) Methodes et compositions de traitement de maladies ophtalmiques par la modulation du retinol serique, de la proteine de liaison de retinol serique (rbp) et / ou de la rbp / du retinol serique
TW200612891A (en) Methods and compositions for treating ophthalmic conditions with retinyl derivatives
WO2007150046A3 (fr) Procédés et compositions pour traiter des conditions ophtalmiques par la modulation de l'activité de mégaline
IN2012DN00352A (fr)
WO2010127099A3 (fr) Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
WO2011083150A3 (fr) Petites molécules pour traiter l'obésité
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
WO2012097213A3 (fr) Méthodes de diagnostic et de traitement de troubles liés à la longueur de l'œil
WO2010062377A3 (fr) Procédés et compositions pour la détection et le traitement de l’éclampsie
AU2016219704A1 (en) Anti-Notch1 antibodies
WO2012170807A3 (fr) Molécules de liaison anti-psl de pseudomonas et leurs utilisations
WO2012100229A3 (fr) Compositions et procédés contre les maladies cardiovasculaires
WO2011091366A3 (fr) Procédés de traitement ou de prévention de la parodontite et maladies associées à la parodontite
WO2009114729A3 (fr) Composés, compositions et procédés de traitement des maladies et des troubles liés au stockage lysosomal
WO2008013984A3 (fr) Compositions et méthodes destinées à traiter et/ou à prévenir des maladies ophtalmologiques
WO2012012278A3 (fr) Compositions et procédés pour le traitement de troubles pathologiques associés à gpr35 et/ou au complexe gpr35-herg
WO2013086323A3 (fr) Compositions d'huile ajoutée et procédés pour une santé améliorée
PH12014501169B1 (en) Thrombin-binding antibody molecules and uses thereof
WO2008135180A3 (fr) Aliment pour animaux domestiques et son procédé de fabrication
WO2011091435A3 (fr) Méthodes de traitement de maladies hépatiques
WO2013022265A3 (fr) Sels antibactériens émettant des rayons infrarouges lointains dans une salinité basse, et leur appareil et leur procédé de préparation
MX359930B (es) Uso de ácido siálico, precursor de ácido siálico o una combinación de los anteriores para preparar medicamentos útiles en una condición diabética o síndrome nefrótico.
MX354727B (es) Composicion para uso en la promocion de absorcion de magnesio y/o retencion de magnesio.
WO2012068332A9 (fr) Méthodes de traitement de troubles neurologiques légers ou à un stade précoce

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880107835.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08834564

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2699773

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 204728

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2010527024

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 584649

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008305303

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008834564

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2711/DELNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20107009129

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2008305303

Country of ref document: AU

Date of ref document: 20080916

Kind code of ref document: A